# Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Canonical URL: https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results
Ticker: CNTX
Company: Context Therapeutics
Source: Context Therapeutics
Published: 2026-05-06 20:18 EST
Original Source URL: https://ir.contexttherapeutics.com
## Summary

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million

## Article Body
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million
## Recent Company News
- 2026-05-27 11:30 EST — [Context Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Context Therapeutics
- 2026-05-18 10:45 EST — [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202](https://biopharmsignal.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202) — Source: Context Therapeutics
- 2026-05-06 20:18 EST — [Context Therapeutics Reports First Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results) — Source: Context Therapeutics
- 2026-04-02 11:30 EST — [Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer) — Source: Context Therapeutics
- 2026-03-23 20:16 EST — [Context Therapeutics Reports Full Year 2025 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-full-year-2025-operating-and-financial-results) — Source: Context Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)